Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank51
3Y CAGR-33.8%
5Y CAGR-13.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-33.8%/yr
Quarterly compound
5Y CAGR
-13.8%/yr
Recent deceleration
Percentile
P51
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.36% |
| Q3 2025 | 8.83% |
| Q2 2025 | 6.87% |
| Q1 2025 | -6.05% |
| Q4 2024 | 7.40% |
| Q3 2024 | 8.48% |
| Q2 2024 | -2.52% |
| Q1 2024 | 19.50% |
| Q4 2023 | 8.32% |
| Q3 2023 | -1.25% |
| Q2 2023 | -1.95% |
| Q1 2023 | 6.38% |
| Q4 2022 | 15.01% |
| Q3 2022 | 13.72% |
| Q2 2022 | -6.45% |
| Q1 2022 | 8.21% |
| Q4 2021 | 20.08% |
| Q3 2021 | -7.91% |
| Q2 2021 | -4.80% |
| Q1 2021 | -1.07% |
| Q4 2020 | 9.20% |
| Q3 2020 | -5.71% |
| Q2 2020 | 25.65% |
| Q1 2020 | -22.73% |
| Q4 2019 | 44.39% |
| Q3 2019 | -43.23% |
| Q2 2019 | 91.54% |
| Q1 2019 | -22.09% |
| Q4 2018 | 7.08% |
| Q3 2018 | 5.22% |
| Q2 2018 | 7.23% |
| Q1 2018 | -6.33% |
| Q4 2017 | 0.29% |
| Q3 2017 | 3.62% |
| Q2 2017 | 1.18% |
| Q1 2017 | 4.22% |
| Q4 2016 | -12.60% |
| Q3 2016 | -7.99% |
| Q2 2016 | 19.11% |
| Q1 2016 | 1.93% |